We have located links that may give you full text access.
Denosumab mid-term densitometric gain in postmenopausal osteoporosis women in clinical practice: comment on "Variability of denosumab densitometric response in postmenopausal osteoporosis".
Rheumatology International 2018 June
We aim to confirm previous observations among postmenopausal osteoporotic women who received denosumab in terms of densitometric changes. We performed an observational clinical practice scenario study assessing baseline bone mineral density and its change after 2 years of treatment in postmenopausal osteoporotic women. Most of our patients were severe and had previous fracture and had received several treatments before denosumab initiation. We observed a 10.06% (± 3.46) improvement in spine, and a 4.87% (± 4.78) improvement in femoral neck. Our findings are in accordance with other authors that suggest denosumab provides densitometric gain in clinical practice in severe postmenopausal osteoporotic women.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app